Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Vaccines: 2023 Year in Review

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

PBM Leaders

Subscribe

Articles

Two years after treatment, both girls show normal motor function and no signs of spinal muscular atrophy symptoms.

Premature Twins Thrive After Early SMA Gene Therapy

A closer look at the available PrEP options available in the United States.

PrEP Overview in Light of Lenacapavir Licensing Agreements 

Here’s what you missed this week on Managed Healthcare Executive.

MHE Week in Review – No HIV in Breast Milk, RSV and More

Laura is the vice president of content of Managed Healthcare Executive

 (MHE) and all its brands, including Formulary Watch

. She has been working on MHE since 2019 and has been with MHE's parent company, MJH Life Sciences

, since 2011. She has an MA in business and economic reporting from New York University.

The regimen has shown promise in preventing graft-versus-host disease in patients who received a haploidentical stem cell transplant.

New Regimen Could Improve Outcomes in Transplantation From Half-Matched Donors

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

ASRS

AIDS Conference

ATS 

AHIP

Asembia’s Specialty Pharmacy Summit

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Authors

Healthcare HR professionals—if they haven’t already—must reshape the workplace each and every day by focusing intently and with new eyes on what matters most during this ongoing pandemic: employees.

Re-Focusing HR in Wake of COVID-19: Tips for Healthcare Professionals

Best Practices in Communicating the Benefits of ART

Video content above is prompted by the following:

What are the best practices in the communication of benefits?

A medical expert in infertility discusses how best practices in communicating benefits for fertility treatments and assisted reproductive technology (ART) programs involve clear, concise and accessible information delivery and tailoring messages to diverse patient populations to ensure comprehensive understanding of coverage options and treatment processes.

Clinical

Video Series

Incorporating Social Determinants of Health in ART

How do you incorporate social determinants of health and population health into your decision-making?

Jeffrey Dunn, Pharm.D., MBA, discusses how social determinants of health and population health factors are integrated into decision-making processes for fertility treatments and assisted reproductive technology (ART) programs to ensure equitable access and improve overall outcomes across diverse patient populations.

Characteristics of a Comprehensive ART Program

What are the components of a good comprehensive fertility/assisted reproductive technology program?

A key opinion leader discusses how comprehensive fertility/ assisted reproductive technology (ART) programs should include a range of services to provide holistic care for individuals and couples seeking to conceive.

Overcoming Barriers in ART

What do you see as overall issues for assisted reproductive technology?

Jeffrey Dunn, Pharm.D., MBA, discusses how the overall issues for assisted reproductive technologies (ARTs) encompass a range of challenges, including access, affordability, efficacy and ethical considerations, and the need for continued research and improvement in treatment protocols

Coverage Considerations for ART Protocols

What are your criteria for ensuring coverage of different assisted reproductive technologies (ARTs)? How have you successfully worked with providers to ensure access?

Do you have a preferred stepwise approach to ensuring coverage of the different ARTs?

What is your approach to coverage on mixed ART protocols? How can providers work with payers to ensure that patients have access to mixed ART protocols?

The key opinion leader discusses how criteria for assisted reproductive technology (ART) coverage are established, including stepwise approaches and considerations for mixed protocols, while emphasizing the importance of collaboration between providers and payers to ensure patient access to various ARTs.

The Importance of Clinical Trials in Infertility

Why is it necessary to have comparison trials for the different assisted reproductive technologies (ARTs) that are used in clinical practice?

What was seen in the trial that compared highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (FSH), and how do these results affect your decision-making?

What was seen in a study that examined health benefit design for ART and its impact on pregnancy outcomes? 

Jeffrey Dunn, Pharm.D., MBA, discusses how comparison trials for different assisted reproductive technologies (ARTs) are necessary to evaluate their relative efficacy, safety and cost-effectiveness, with specific focus on a trial comparing highly purified human menotropin (HP-hMG) and recombinant follicle-stimulating hormone (FSH), as well as a study examining the impact of health benefit design for ART on pregnancy outcomes.

Diane Psaras

Articles

Latest Updated Articles